Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Gains from Sales and Divestitures (2016 - 2021)

Medifast's Gains from Sales and Divestitures history spans 7 years, with the latest figure at $26000.0 for Q3 2021.

  • For Q3 2021, Gains from Sales and Divestitures fell 13.33% year-over-year to $26000.0; the TTM value through Sep 2021 reached $26000.0, down 13.33%, while the annual FY2020 figure was $32000.0, 88.29% down from the prior year.
  • Gains from Sales and Divestitures reached $26000.0 in Q3 2021 per MED's latest filing, up from $25000.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $273300.0 in Q4 2019 to a low of $14000.0 in Q1 2021.
  • Average Gains from Sales and Divestitures over 5 years is $70819.7, with a median of $32000.0 recorded in 2019.
  • The largest YoY upside for Gains from Sales and Divestitures was 200.33% in 2019 against a maximum downside of 90.0% in 2019.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $120000.0 in 2017, then decreased by 24.17% to $91000.0 in 2018, then soared by 200.33% to $273300.0 in 2019, then tumbled by 88.29% to $32000.0 in 2020, then decreased by 18.75% to $26000.0 in 2021.
  • Per Business Quant, the three most recent readings for MED's Gains from Sales and Divestitures are $26000.0 (Q3 2021), $25000.0 (Q2 2021), and $14000.0 (Q1 2021).